Arlo J. Loutan

Arlo J. Loutan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arlo J. Loutan has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Matthias Götte

    Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada

    2 shared publications
  • Adam Montoya

    Calibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, CA 92037, USA

    1 shared publication
  • Anant Gharpure

    Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA

    1 shared publication
  • Andrew B. Ward

    Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA

    1 shared publication
  • Anil K. Gupta

    Calibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA

    1 shared publication
  • Arnab K. Chatterjee

    Calibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA

    1 shared publication

Latest Publications

  • Open Access

    Substrate and target selectivity of 4′-fluoroadenosine against viral and host polymerases

    by Simon M. Walker, Arlo J. Loutan, Egor P. Tchesnokov, Dana Kocincova, Calvin J. Gordon, Ruby A. Escobedo, Nathaniel Jackson, Olivia A. Vogel, Kim Morsheimer, Suncheol Park, et al.

  • Open Access

    Bunyaviral Cap-Snatching Endonuclease Activity and Inhibition with Baloxavir-like Inhibitors in the Context of Full-Length L Proteins

    by Arlo J. Loutan, Baiuyan Yang, Gabrielle Connolly, Adam Montoya, Robert J. Smiley, Arnab K. Chatterjee, Matthias Götte

    The Bunyavirales order includes a range of zoonotic viruses, which can cause severe disease in humans. The viral replication machinery is a logical target for the development of direct-acting antivirals. Inhibition of the cap-snatching endonuclease activity of related influenza viruses provides a proof of concept. Using the influenza B virus (IBV) RNA-dependent RNA polymerase complex as a benchmark, we conducted a comparative analysis of endonuclease activities of recombinant full-length bunyaviral L proteins using gel-based assays. The IBV complex demonstrates specific endonucleolytic cleavage and a clear preference for capped substrates. In contrast, severe fever with thrombocytopenia syndrome, Sin Nombre, and Hantaan virus L proteins readily cleave capped and uncapped RNAs to a broader spectrum of RNA fragments. Active site mutants further help to control for the potential of contaminating nucleases, exonuclease activity, and RNA hydrolysis. The influenza cap-snatching inhibitor baloxavir and derivatives have been used to validate this approach. In conclusion, the results of this study demonstrate the importance of assays with single nucleotide resolution and the use of full-length L proteins as a valuable experimental tool to identify selective endonuclease inhibitors.